Przejdź do zawartości
Merck

F6800

Fenoldopam monohydrobromide

≥98%

Synonim(y):

6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol monohydrobromide, SKF-82526

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość


Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C16H16ClNO3 · HBr
Numer CAS:
Masa cząsteczkowa:
386.67
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
266-634-7
MDL number:
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

Nazwa produktu

Fenoldopam monohydrobromide, ≥98%

InChI key

DSGOSRLTVBPLCU-UHFFFAOYSA-N

InChI

1S/C16H16ClNO3.BrH/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;/h1-4,7,13,18-21H,5-6,8H2;1H

SMILES string

ClC1=C(O)C(O)=CC2=C1CCNCC2C3=CC=C(O)C=C3.[H]Br

assay

≥98%

form

solid

storage condition

protect from light
under inert gas

color

off-white

solubility

DMSO: >12 mg/mL
H2O: 4.75 mg/mL

storage temp.

2-8°C

Gene Information

Biochem/physiol Actions

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.

Features and Benefits

This compound was developed by Hospira. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Ta strona może zawierać tekst przetłumaczony maszynowo.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Sens. 1

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

P A de Vries et al.
Journal of cardiovascular pharmacology, 34(2), 191-198 (1999-08-13)
The natriuretic response to a dopamine 1-like receptor agonist is blunted in spontaneously hypertensive rats (SHRs). Whether the renal vasodilator response to D1-like receptor stimulation in SHRs is defective also is unclear. To determine whether the renal hemodynamic response to
M Quevedo et al.
General pharmacology, 32(1), 123-125 (1999-01-15)
1. Fenoldopam mesylate, a benzazepine derivative, is a D1 receptor agonist that lowers blood pressure through vasodilation of renal, mesenteric, coronary and cerebral vascular beds. 2. Experiments were performed in rats, and mean carotid blood pressure and heart rate were
T Hussain et al.
The American journal of physiology, 272(3 Pt 2), F339-F346 (1997-03-01)
The dopamine DA1 receptor transduces its signal via adenylyl cyclase and phospholipase C in the renal proximal tubule, which has been suggested to be defective at the level of receptor-G protein coupling in spontaneously hypertensive rats (SHR). We prepared basolateral
R A Hahn et al.
The Journal of pharmacology and experimental therapeutics, 223(2), 305-313 (1982-11-01)
SK&F 82526 (6-chloro-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-(1H)-3-benzazepine) was evaluated for its peripheral cardiovascular activity, effect on renal and central dopamine receptors and mechanism of action. Comparisons were made with dopamine. In anesthetized dogs, SK&F 82526 i.v., produced dose-related dilation of the renal vasculature, apparently
Jerome F O'Hara et al.
Urology, 81(2), 340-345 (2013-02-05)
To test the hypothesis that fenoldopam administration ameliorates ischemic injury, preserving the glomerular filtration rate and serum creatinine postoperatively after partial nephrectomy in patients with a solitary kidney. Fenoldopam is a short-acting dopamine-1 receptor agonist that might provide renal protection

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej